Nicox S.A. (EPA:ALCOX)
0.3900
+0.0035 (0.91%)
Aug 3, 2026, 1:41 PM CET
Nicox Revenue
In the year 2025, Nicox had annual revenue of 16.77M EUR with 113.41% growth. Nicox had revenue of 15.25M in the half year ending December 31, 2025.
Revenue
16.77M
Revenue Growth
+113.41%
P/S Ratio
2.03
Revenue / Employee
1.68M
Employees
10
Market Cap
34.06M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.77M | 8.91M | 113.41% |
| Dec 31, 2024 | 7.86M | 955.64K | 13.84% |
| Dec 31, 2023 | 6.90M | 899.20K | 14.98% |
| Dec 31, 2022 | 6.00M | -3.42M | -36.30% |
| Dec 31, 2021 | 9.43M | -6.08M | -39.21% |
| Dec 31, 2020 | 15.51M | 8.65M | 126.20% |
| Dec 31, 2019 | 6.86M | 2.83M | 70.23% |
| Dec 31, 2018 | 4.03M | 1.72M | 74.71% |
| Dec 31, 2017 | 2.31M | 2.29M | 14,306.25% |
| Dec 31, 2016 | 16.00K | -51.00K | -76.12% |
| Dec 31, 2015 | 67.00K | -5.92M | -98.88% |
| Dec 31, 2014 | 5.98M | 5.55M | 1,272.02% |
| Dec 31, 2013 | 436.00K | -7.18M | -94.27% |
| Dec 31, 2012 | 7.61M | 6.75M | 779.21% |
| Dec 31, 2011 | 866.00K | -6.56M | -88.33% |
| Dec 31, 2010 | 7.42M | 6.30M | 563.36% |
| Dec 31, 2009 | 1.12M | -2.24M | -66.72% |
| Dec 31, 2008 | 3.36M | -17.26M | -83.70% |
| Dec 31, 2007 | 20.62M | 10.99M | 114.12% |
| Dec 31, 2006 | 9.63M | 3.10M | 47.52% |
| Dec 31, 2005 | 6.53M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 28.60M |
| Fermentalg | 13.38M |
| Poxel | 7.66M |
| Advicenne | 6.40M |
| MaaT Pharma | 4.52M |
| ABIONYX Pharma | 4.06M |
| Adocia | 3.85M |
| OSE Immunotherapeutics | 2.69M |
Nicox News
- 1 year ago - Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights - GlobeNewsWire
- 1 year ago - Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results - GlobeNewsWire
- 2 years ago - Nicox Provides Second Quarter 2024 Update - GlobeNewsWire
- 2 years ago - Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results - GlobeNewsWire
- 2 years ago - Nicox Provides Fourth Quarter 2023 Financial and Business Highlights - GlobeNewsWire
- 3 years ago - Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones - GlobeNewsWire
- 3 years ago - Nicox Provides Second Quarter 2023 Financial and Business Highlights - GlobeNewsWire
- 3 years ago - Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress - GlobeNewsWire